Detection of polymyxin B resistance in Enterobacterales by broth disk elution method
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20231698Keywords:
Extensively drug resistant, Enterobacterales, Colistin, Polymyxin, Multi-drug resistance, Life-saving drugAbstract
Background: Antibiotic resistance being the critical issue faced by medical field, especially by Gram negative bacteria. It is a great threat in the case of both hospitals acquired and community acquired infections. They possess various mechanisms for their survival. The widespread resistance in Gram negative bacteria has necessitated evaluation of the use of older antimicrobials such as polymyxins. Polymyxins are disfavoured owing to their potential clinical toxicity, especially nephrotoxicity. Thus, they got abandoned in the sixties. But now they are re- emerged and used as last resort antibiotics.
Methods: 274 isolates of Enterobacterales including Klebsiella pneumoniae, Escherichia coli, Citrobacter spp. Enterobacter spp. was collected from various diagnostic microbiology laboratories in Kerala. The polymyxin resistance among Enterobacterales by broth disk elution method recommended by CLSI.
Results: In this study prevalence of multi drug resistant is 37% and extensively drug resistant strains is 25%. And the threatening fact is that the colistin also shows resistance among Enterobacterales (9.2%).
Conclusions: Though the resistance to Polymyxin B is to the lesser side in the present study, increase in resistance to the agent is being documented globally elsewhere. So, rational use of Polymyxin B is warrantied as we could cherish polymyxin B as a “life - saving drug” to avoid no drug available. Knowledge of antimicrobial resistance and development of new antimicrobial agents and improved treatments are essential in the current situation.
References
Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res. 2006;4:138-46.
Arnold TM, Forrest GN, Messmer KJ. Polymyxin antibiotics for Gram-negative infections. Am J Health Syst Pharm. 2007;64:819-26.
Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassoupoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis. 2005;5:24.
Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. colistin treatment in patients with ICU-acquired infections caused by multi-resistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115-21.
Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci. 2018;6(1):1.
Sabino S, Soares S, Ramos F, Moretti M. A cohort study of the impact of carbapenemresistant Enterobacteriaceae infections on mortality of patients presenting with sepsis. Sphere. 2019;4(2):e00052-19.
Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multi-resistant Gram-negative bacteria. Ann Pharmacother. 1999;33:960-7.
Li Z, Cao Y, Yi L, Liu J-H, Yang Q. Emergent Polymyxin Resistance: End of an Era? Open Forum Infect Dis. 2019;6(10):ofz368.
Pogue JM, Ortwine JK, Kaye KS. 2017 Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect. 2021;23:229-33.
Littlewood JM, Koch C, Lambert PA, Hoiby N, Elborn JS, Conway SP, et al. A ten year review of colomycin. Respir Med. 2000;94:63-71.
Tsuji BT, Pogue JM, Zavascki AP, Paul M. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and 4 N.C. Cielo et al. / Diagnostic Microbiology and Infectious Disease 98 (2020) 115099 Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10-39.
Hogardt M, Schmoldt S, Gotzfried M, Adler K, Hessemann J. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother. 2004;54:1057-61.
M02 - Performance Standards for Antimicrobial Disk Susceptibility Tests, 13th Edition. Clinical and Laboratory Standards Institute. 2021.
M100 - Performance Standards for Antimicrobial Susceptibility Testing, 29th Edition. Clinical and Laboratory Standards Institute. 2021.
Ramakrishna MS, Abimannan GC, Jeyamani L, Ramalingam A, Anbalagan K. Burden of Multidrug Resistant Escherichia coli among Patients with Urinary Tract Infections in a Tertiary Care Centre- A Retrospective Analysis. J Clin Diagn Res. 2021;15(9):DC01-6.
Kumar KS, Asina PA, Theckel PG, Divakaran B, Sathar S, Asalatha R, Remya VS. Prevalence of multidrug resistant uropathogens isolated from different age groups in South-India: a cross-sectional study. Int J Res Med Sci. 2022;10:905-12.
Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, et al. Evaluation of susceptibility testing methods for polymyxin. Int J Infect Dis. 2010;14(7):e596-601.
Bir R, Gautam H, Arif N, Chakravarti P, Verma J, Banerjee S, et al. Analysis of colistin resistance in carbapenem-resistant Enterobacterales and XDR Klebsiella pneumoniae. Ther Adv Infect Dis. 2022;9:87-9.
